Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
divarasib + pembrolizumab + carboplatin + pemetrexed
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a **combination regimen** of four active agents used in investigational and early-phase clinical trials for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with KRAS G12C mutation[3][5][7]. The regimen consists of: - **Divarasib**: an orally active small molecule inhibitor targeting KRAS G12C mutant protein, blocking oncogenic signaling. - **Pembrolizumab**: a monoclonal antibody immune checkpoint inhibitor (anti-PD-1), enhancing antitumor immune response. - **Carboplatin**: a platinum-based chemotherapy agent causing DNA crosslinking and apoptosis. - **Pemetrexed**: a folate antimetabolite chemotherapy which inhibits multiple enzymes involved in purine and pyrimidine synthesis. This combination seeks to leverage KRAS-mutant targeted therapy, immunotherapy, and chemotherapy synergistically. Trials are ongoing to evaluate efficacy, safety, and dosing in newly diagnosed, previously untreated advanced NSCLC patients[3][7].
- Other names
- divarasib + pembrolizumab + carboplatin + pemetrexed
02
Targets
DNAKRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on divarasib + pembrolizumab + carboplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on divarasib + pembrolizumab + carboplatin + pemetrexed.